Proliferative Vitreoretinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major proliferative vitreoretinopathy markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.45% during 2024-2034.
The proliferative vitreoretinopathy market has been comprehensively analyzed in IMARC's new report titled "Proliferative Vitreoretinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Proliferative vitreoretinopathy is a condition that impairs the retina, which is the light-sensitive covering of tissue at the back of the eye. This disease occurs when cells within the retina grow and multiply abnormally, causing scar tissue that results in vision loss or blindness. The severity of symptoms can vary greatly depending on the scar tissues' extent and location. Individuals suffering from the ailment may experience visual problems, including floaters or flashes of light, peripheral (side) or central loss of vision, reduced visual field, decreased visual acuity, sensitivity to light, etc. The diagnosis of the disease typically requires a combination of in-depth patient history and clinical features. Physical examination and medical history can provide detailed information on the disease frequency and duration, as well as any associated health conditions. The healthcare provider may also perform a dynamic ultrasound examination, which can detect the presence of retinal detachment, along with specific characteristics of proliferative vitreoretinopathy, to confirm a diagnosis.
The increasing cases of eye trauma, retinal detachment, surgical manipulations, etc., which trigger a reactive process of the ocular tissue against cytokines and inflammatory mediators, are primarily driving the proliferative vitreoretinopathy market. Moreover, the rising prevalence of various associated risk factors, such as a smoking history, complicated cataract surgery, a large retinal tear, diabetes, severe nearsightedness, etc., is also bolstering the market growth. Besides this, the escalating utilization of scleral buckling surgery for the treatment of proliferative vitreoretinopathy is acting as another significant growth-inducing factor. This operation involves the placement of a silicone rubber or sponge piece outside the eyeball to support the retina for complete healing, thereby improving the quality of life for patients. Furthermore, the growing application of colchicine and taxol, which respectively inhibit and stabilize microtubule formation to reduce migration and proliferation of cells, is also positively influencing the market. Apart from this, the emerging popularity of the intravitreal formulation of methotrexate owing to its several benefits, including being vitreous-compatible and having an optimized administration volume, is expected to drive the proliferative vitreoretinopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the proliferative vitreoretinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for proliferative vitreoretinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the proliferative vitreoretinopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the proliferative vitreoretinopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the proliferative vitreoretinopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current proliferative vitreoretinopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the proliferative vitreoretinopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the proliferative vitreoretinopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the proliferative vitreoretinopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with proliferative vitreoretinopathy across the seven major markets?
What is the size of the proliferative vitreoretinopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of proliferative vitreoretinopathy?
What will be the growth rate of patients across the seven major markets?
Proliferative Vitreoretinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for proliferative vitreoretinopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the proliferative vitreoretinopathy market?
What are the key regulatory events related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by status related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by phase related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by route of administration related to the proliferative vitreoretinopathy market?
The proliferative vitreoretinopathy market has been comprehensively analyzed in IMARC's new report titled "Proliferative Vitreoretinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Proliferative vitreoretinopathy is a condition that impairs the retina, which is the light-sensitive covering of tissue at the back of the eye. This disease occurs when cells within the retina grow and multiply abnormally, causing scar tissue that results in vision loss or blindness. The severity of symptoms can vary greatly depending on the scar tissues' extent and location. Individuals suffering from the ailment may experience visual problems, including floaters or flashes of light, peripheral (side) or central loss of vision, reduced visual field, decreased visual acuity, sensitivity to light, etc. The diagnosis of the disease typically requires a combination of in-depth patient history and clinical features. Physical examination and medical history can provide detailed information on the disease frequency and duration, as well as any associated health conditions. The healthcare provider may also perform a dynamic ultrasound examination, which can detect the presence of retinal detachment, along with specific characteristics of proliferative vitreoretinopathy, to confirm a diagnosis.
The increasing cases of eye trauma, retinal detachment, surgical manipulations, etc., which trigger a reactive process of the ocular tissue against cytokines and inflammatory mediators, are primarily driving the proliferative vitreoretinopathy market. Moreover, the rising prevalence of various associated risk factors, such as a smoking history, complicated cataract surgery, a large retinal tear, diabetes, severe nearsightedness, etc., is also bolstering the market growth. Besides this, the escalating utilization of scleral buckling surgery for the treatment of proliferative vitreoretinopathy is acting as another significant growth-inducing factor. This operation involves the placement of a silicone rubber or sponge piece outside the eyeball to support the retina for complete healing, thereby improving the quality of life for patients. Furthermore, the growing application of colchicine and taxol, which respectively inhibit and stabilize microtubule formation to reduce migration and proliferation of cells, is also positively influencing the market. Apart from this, the emerging popularity of the intravitreal formulation of methotrexate owing to its several benefits, including being vitreous-compatible and having an optimized administration volume, is expected to drive the proliferative vitreoretinopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the proliferative vitreoretinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for proliferative vitreoretinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the proliferative vitreoretinopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the proliferative vitreoretinopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the proliferative vitreoretinopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current proliferative vitreoretinopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the proliferative vitreoretinopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the proliferative vitreoretinopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the proliferative vitreoretinopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with proliferative vitreoretinopathy across the seven major markets?
What is the size of the proliferative vitreoretinopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of proliferative vitreoretinopathy?
What will be the growth rate of patients across the seven major markets?
Proliferative Vitreoretinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for proliferative vitreoretinopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the proliferative vitreoretinopathy market?
What are the key regulatory events related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by status related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by phase related to the proliferative vitreoretinopathy market?
What is the structure of clinical trial landscape by route of administration related to the proliferative vitreoretinopathy market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PROLIFERATIVE VITREORETINOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PROLIFERATIVE VITREORETINOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PROLIFERATIVE VITREORETINOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PROLIFERATIVE VITREORETINOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PROLIFERATIVE VITREORETINOPATHY - UNMET NEEDS
10 PROLIFERATIVE VITREORETINOPATHY - KEY ENDPOINTS OF TREATMENT
11 PROLIFERATIVE VITREORETINOPATHY - MARKETED PRODUCTS
11.1 List of Proliferative Vitreoretinopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PROLIFERATIVE VITREORETINOPATHY - PIPELINE DRUGS
12.1 List of Proliferative Vitreoretinopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 ADX 2191 - Aldeyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PROLIFERATIVE VITREORETINOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PROLIFERATIVE VITREORETINOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PROLIFERATIVE VITREORETINOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Proliferative Vitreoretinopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Proliferative Vitreoretinopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Proliferative Vitreoretinopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Proliferative Vitreoretinopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Proliferative Vitreoretinopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Proliferative Vitreoretinopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Proliferative Vitreoretinopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Proliferative Vitreoretinopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
16 PROLIFERATIVE VITREORETINOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PROLIFERATIVE VITREORETINOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PROLIFERATIVE VITREORETINOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PROLIFERATIVE VITREORETINOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PROLIFERATIVE VITREORETINOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PROLIFERATIVE VITREORETINOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PROLIFERATIVE VITREORETINOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PROLIFERATIVE VITREORETINOPATHY - UNMET NEEDS
10 PROLIFERATIVE VITREORETINOPATHY - KEY ENDPOINTS OF TREATMENT
11 PROLIFERATIVE VITREORETINOPATHY - MARKETED PRODUCTS
11.1 List of Proliferative Vitreoretinopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PROLIFERATIVE VITREORETINOPATHY - PIPELINE DRUGS
12.1 List of Proliferative Vitreoretinopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 ADX 2191 - Aldeyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PROLIFERATIVE VITREORETINOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PROLIFERATIVE VITREORETINOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PROLIFERATIVE VITREORETINOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Proliferative Vitreoretinopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Proliferative Vitreoretinopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Proliferative Vitreoretinopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Proliferative Vitreoretinopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Proliferative Vitreoretinopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Proliferative Vitreoretinopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Proliferative Vitreoretinopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Proliferative Vitreoretinopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Proliferative Vitreoretinopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Proliferative Vitreoretinopathy - Access and Reimbursement Overview
16 PROLIFERATIVE VITREORETINOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PROLIFERATIVE VITREORETINOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PROLIFERATIVE VITREORETINOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
